2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 770

Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays
Abstract Number: 131

Detection of Synovitis and Erosions with an Automated Ultrasound System: Data from a Prospective Cohort with Early and Established RA
Abstract Number: 2390

Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Abstract Number: 1857

Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Abstract Number: 1925

Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients
Abstract Number: 412

Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK-1
Abstract Number: L14

Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Abstract Number: 708

Determining Risk Factors That Increase Hospitalizations in Patients with Systemic Lupus Erythematosis
Abstract Number: 2997

Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients
Abstract Number: 357

Development and Validation of a Diagnostic Bead-Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect “Seronegative” Rheumatoid Arthritis
Abstract Number: 2716

Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Abstract Number: 771

Development of a Bifluorescent Lineage Tracker Reporter Mouse Strain to Analyze the Phenotypic Conversion of Endothelial Cells into Myofibroblasts in Vivo. Application to Study the Synergistic Effects of Endothelin-1 on TGF-β1-Induced Endothelial-to-Mesenchymal Transition
Abstract Number: 2999

Development of a Composite Index for Clinical Trials in Early Diffuse Cutaneous Systemic sclerosis—the Combined Response Index in Systemic Sclerosis
Abstract Number: 291

Development of a Serious Game Designed for Children with Juvenile Idiopathic Arthritis
Abstract Number: 1304

Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].